|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
In 2004, the Neurotech Index was up 27.1% compared to respective gains of 10.9% and 8.6% for the S&P 500 and the NASDAQ Composite Index. The Neurotech Index also outpaced the NASDAQ Biotechnology Index, another life-sciences-oriented measure of the public markets, which grew by 5.1% in 2004. Neurological disease and psychiatric illness represent the largest and fastest growing unmet medical market: over 1.5 billion people worldwide ad 100 million individuals in North America alone. The neurotechnology industry has three sectors: neuropharmaceuticals with revenues of $87 billion and 13 percent growth annually; neurodevices with revenues of $2.8 billion and 20% growth annually; and neurodiagnostics with revenues of $12 billion and 11 percent growth annually. VC investment in neurotechnology companies climbed 225% from 1999 to 2004, representing $6 billion. According to data compiled by NeuroInsights, today, one-in-four VC dollars invested in Life Sciences goes to companies creating innovations in neuropharmaceuticals, neurodevices and neurodiagnostics. “Five of the top ten leading causes of disability worldwide are caused by problems with the brain and nervous system,” explained Zack Lynch, managing director of Neuroinsights.“ Neurotechnology represents a safer, cost-effective
means to treat neurological and psychiatric disorders. Neurotechnology, unlike genetic engineering,
and pharmaceuticals is flexible and versatile. We believe our technology
will become the treatment of choice because of the unknown and potentially
irreversible effects associated with genetic engineering and many of
today’s drug therapies. Given the cost-benefit ratio we also believe
insurance providers will likely approve and embrace this as a covered
benefit. |
|
|
|